# Lauxera Capital Partners

> Lauxera Capital Partners is a VC fund backing Health Care and Medical Device. See 14 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Paris, France
- Total investments: 14
- Last investment: Jul 2026
- Lead investor: 64%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/lauxera-capital-partners/?viewAsMember=true
- X (Twitter): https://twitter.com/home?lang=fr
- Website: https://lauxera.com/

Lauxera Capital Partners is an independent, international, healthcare-focused asset management company. Our growth equity investments focus primarily on commercial-stage medical devices, digital health, life sciences tools, and healthcare data companies. Led by entrepreneurial company builders and seasoned healthcare investors with experienceacross international markets, we empower European healthtech entrepreneurs to deliver the growth promised by their innovations.Lauxera was created in 2020 and has offices in Paris and San Francisco.

## Contacts

5 contacts available for Lauxera Capital Partners. Shizune tracks 3 team members at Lauxera Capital Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/lauxera-capital-partners?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $20M–$22M |
| Series C | $55M–$130M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 6 | 43% |
| Medical Device | 6 | 43% |
| Biotechnology | 5 | 36% |
| Medical | 2 | 14% |
| Software | 2 | 14% |

25 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 3 | 21% |
| Series A | 2 | 14% |
| Funding Round | 2 | 14% |
| Private Equity | 2 | 14% |
| Venture - Series Unknown | 2 | 14% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 2 | 14% |
| Sweden | 2 | 14% |
| United States | 2 | 14% |
| China | 1 | 7% |
| Denmark | 1 | 7% |

9 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Alex Slack | Co-Founder | 2 | https://shizune.co/investors/profile/alex-slack |
| Samuel Levy | Founding Partner | 5 | https://shizune.co/investors/profile/dr-samuel-levy |
| Victor Decrion | Managing Partner | 1 | https://shizune.co/investors/profile/victor-decrion-1ffa |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| GenePlanet | GenePlanet is a European company active in the field of biotechnology, specializing in genetic testing and research. They specialize in preventive genetic tests that are intended for the end user, but they also offer clinical genetic tests which help doctors with their therapeutic procedures. Their tests adhere to the highest standards of qualityand are based on the latest scientific discoveries. They provide people with information which can help them adjust their lifestyle accordingly and take measures that will provide additional protection from health risks due to genetic predispositions. |  | Secondary Market | Jul 30, 2026 |  |
| OrganOx | OrganOx Limited was founded in 2008 to exploit normothermic preservation technology invented by Prof Peter Friend and colleagues and further developed by Prof Constantin Coussios at the University of Oxford. | $160M | Venture - Series Unknown | Feb 24, 2025 |  |
| Acandis | Acandis GmbH offers Engineering Stroke Solutions, Flow Diverter, Stent Retriever, Embolisation Devices, Acute Stroke Care, Thrombectomy, and PTA. They provide medical devices and products for the treatment of neurovascular diseases for patients. If anyone wants to contact them please contact them via phone call or email. | $52.1M | Private Equity | Jan 22, 2025 |  |
| Acandis | Acandis GmbH offers Engineering Stroke Solutions, Flow Diverter, Stent Retriever, Embolisation Devices, Acute Stroke Care, Thrombectomy, and PTA. They provide medical devices and products for the treatment of neurovascular diseases for patients. If anyone wants to contact them please contact them via phone call or email. | $52M |  | Jan 22, 2025 |  |
| Acandis | Acandis GmbH offers Engineering Stroke Solutions, Flow Diverter, Stent Retriever, Embolisation Devices, Acute Stroke Care, Thrombectomy, and PTA. They provide medical devices and products for the treatment of neurovascular diseases for patients. If anyone wants to contact them please contact them via phone call or email. | $52M |  | Jan 22, 2025 |  |
| Synovo Group | Synovo Group provides digital services and software publishing services for medical transport professionals. They are involved in hosting, infrastructure, cloud and telecom, supports companies in their digital transition. They offer hosting and outsourcing service that complies with the requirements of the HDS standard in terms of hosting healthdata. Their services include IT solutions, telecom, cloud services, sale of hardware and software, infrastructure hosting and outsourcing security consultancy, and data center. | $14.5M | Venture - Series Unknown | Sep 24, 2024 |  |
| Jiaozhiwu | Jiaozhiwu is a food-tech brand that specializes in the research and development of synthetic biology in functional food ingredients and nutritional health products. | $20M | Series A | Jun 04, 2024 |  |
| Natural Cycles | Natural Cycles offers a contraceptive app, spearheading digital contraception, a new category in female reproductive health.Users measure their basal body temperature in the morning and the app computes the temperature (and other relevant data like levels of luteinizing hormone) through an algorithm to calculate whether they are fertile or not.Natural Cycles’ subscription product relies on an algorithmic method to predict which days women are fertile during their monthly cycle — with an in-app color-coded calendar informing users if they could have unprotected sex on a given day or not.Women using the app are required to measure and input their body temperature daily using a basal thermometer. Natural Cycles relies on this and other individual data inputs to algorithmically calculate the probability of the user being fertile on each day in her cycle. | $55M | Series C | May 29, 2024 |  |
| BioLamina | BioLamina is a biotechnology company with a global presence, offering cell culture matrices for primary cells. |  |  | Sep 12, 2023 |  |
| Veranex | Veranex is the first truly end-to-end, global, tech-enabled, concept-through-commercialization service provider that focuses solely on medical technology: medical device, diagnostics, companion diagnostics, digital health, and drug delivery. For all your needs through the entire medical device clinical trial process, Veranex is transforming medtechinnovations. |  | Private Equity | May 19, 2022 |  |

10 of 14 investments shown.

## Co-investors
- [Intel Capital](https://shizune.co/investors/profile/intel-capital) — VC Fund, 2 deals together
- [Accelmed](https://shizune.co/investors/profile/accelmed) — VC Fund, 1 deal together
- [Arkin Digital Health](https://shizune.co/investors/profile/arkin-digital-health) — VC Fund, 1 deal together
- [BlackRock](https://shizune.co/investors/profile/blackrock) — VC Fund, 1 deal together
- [Bonnier Capital](https://shizune.co/investors/profile/bonnier-ventures) — VC Fund, 1 deal together
- [Bure Equity AB](https://shizune.co/investors/profile/bure-equity-ab) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

### Similar country
- [Vaekstfonden](https://shizune.co/investors/profile/v%C3%A6kstfonden) — VC Fund
- [PSV](https://shizune.co/investors/profile/preseed-innovation) — VC Fund
- [Seed Capital](https://shizune.co/investors/profile/seed-capital) — VC Fund

## Featured in investor lists
- [Medical Device Investors in Denmark](https://shizune.co/investors/medical-device-investors-denmark)
- [Medical Device VC Funds in Denmark](https://shizune.co/investors/medical-device-vc-funds-denmark)
- [Biotechnology Investors in Denmark](https://shizune.co/investors/biotechnology-investors-denmark)
- [Biotechnology VC Funds in Denmark](https://shizune.co/investors/biotechnology-vc-funds-denmark)
- [Biotech VC Funds in Denmark](https://shizune.co/investors/biotech-vc-funds-denmark)
- [Health Care VC Funds in Denmark](https://shizune.co/investors/health-care-vc-funds-denmark)

## FAQ

### What does Lauxera Capital Partners invest in?

Lauxera Capital Partners invests primarily in Health Care, Medical Device and Biotechnology startups, most often at Series C and Series A stage. Most of the 14 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Lauxera Capital Partners's check size?

Lauxera Capital Partners typically joins rounds of $20M–$22M at Series A and $55M–$130M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Lauxera Capital Partners participates in.

### How do I contact Lauxera Capital Partners?

Public channels for Lauxera Capital Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Lauxera Capital Partners?

The team at Lauxera Capital Partners includes Alex Slack (Co-Founder), Samuel Levy (Founding Partner) and Victor Decrion (Managing Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co